Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2018027409
Abstract: Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. This single-group, multicenter phase 2 study assessed the safety and… read more here.
Keywords: newly diagnosed; myeloid leukemia; acute myeloid; phase study ... See more keywords
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007334
Abstract: Key points In the phase 3 PANTHER trial, EFS was similar between arms in the intent-to-treat population and in patients with higher-risk MDS. A signal for improved overall survival for pevonedistat+azacitidine was seen in higher-risk… read more here.
Keywords: risk mds; pevonedistat plus; higher risk; plus azacitidine ... See more keywords
Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model
Sign Up to like & getrecommendations! Published in 2022 at "Oncotarget"
DOI: 10.18632/oncotarget.28331
Abstract: Antibody drug conjugates (ADC) are one of the attractive modalities for the treatment of acute myeloid leukemia (AML). Previously, we have developed ASP1235, a novel ADC targeting Fms-like tyrosine kinase 3 (FLT3) which is widely… read more here.
Keywords: effect; combination; plus azacitidine; model ... See more keywords